Top Markets
#1 Islamic Coin Islamic Coin +154.39%
#2 PulseChain PulseChain +49.22%
#3 BOOK OF MEME BOOK OF MEME +26.04%
#4 Starpower Starpower +19.59%
#5 RedStone RedStone +16.92%
#6 Lighter Lighter +12.26%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.08%
#8 Monad Monad +10.36%
#9 edgeX edgeX +10.32%
#10 Bio Protocol Bio Protocol +9.97%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
TMS Co., Ltd. TMS Co., Ltd.

TMS Co., Ltd.

4891
Rank in Stocks #27373
Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on... Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.
Share Price
$0.73072946
Market Cap
$33.30M
Change (1 day)
0.00%
Change (1 year)
-31.85%
Country
JP
Trade TMS Co., Ltd. (4891)

Category

Healthcare
Revenue for TMS Co., Ltd. (4891)
Revenue in Aug 2026 TTM: 0
According to TMS Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for TMS Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH